Neurogene price target lowered to $45 from $60 at BMO Capital
PremiumThe FlyNeurogene price target lowered to $45 from $60 at BMO Capital
4M ago
Neurogene Inc. Faces Uncertainty with NGN-101 Program Amid FDA Challenges and Strategic Hurdles
Premium
Company Announcements
Neurogene Inc. Faces Uncertainty with NGN-101 Program Amid FDA Challenges and Strategic Hurdles
4M ago
Neurogene price target lowered to $45 from $60 at BMO Capital
Premium
The Fly
Neurogene price target lowered to $45 from $60 at BMO Capital
4M ago
Neurogene Adjusts NGN-401 Trial After Adverse Event
PremiumCompany AnnouncementsNeurogene Adjusts NGN-401 Trial After Adverse Event
5M ago
Neurogene provides update on NGN-401 clinical trial for Rett syndrome
Premium
The Fly
Neurogene provides update on NGN-401 clinical trial for Rett syndrome
5M ago
Neurogene provides update on NGN-401 clinical trial for Rett syndrome
Premium
The Fly
Neurogene provides update on NGN-401 clinical trial for Rett syndrome
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100